A carregar...
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to standard treatments, such as docetaxel and enzalutamide. Histone deacetylase (HDAC) inhibitors showed promising results in hematological malignancies, but they failed in solid tumors s...
Na minha lista:
| Publicado no: | Biomedicines |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7168248/ https://ncbi.nlm.nih.gov/pubmed/32019149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8020022 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|